{"product_id":"from-clones-to-claims","title":"From Clones to Claims","description":"\u003cp\u003e»From Clones to Claims« has evolved as a reaction to the ready internet availability of all decisions of the Boards of Appeal of the European Patent Office (EPO). While the increased availability is one thing, using the information in daily practice is another. This translation is the aim of the 7th edition of this book. It has become a guide through the available decisions not only of Boards 3.3.04 and 3.3.08   the initial biotech Boards   but also of Boards 3.3.01 and 3.3.02, which have meanwhile also begun to hear biotech cases. This reflects the overwhelming development and expansion of biotech into the field of biopharmaceuticals, for example, the advent of antibody drugs against several types of life-threatening cancer and chronic diseases, such as rheumatoid arthritis. One of the best current examples of the importance of biopharmaceuticals was the virtually immediate advent of powerful vaccines against the causative agent of the corona (SARS-CoV-2\/Covid-19) pandemic. »From Clones to Claims« contains extra chapters on the patenting of viruses   and related vaccines. This is just one example of the chapters in the expanded version. This 7th edition also contains other supplemental chapters in view of recent developments in science and related jurisprudence. For example, new or substantially revised chapters include a new, more elaborate chapter on SPCs; a new chapter on plausibility, with express consideration of pending case G 2\/21; as well as new chapters on next generation sequencing technologies and personalized medicines\/companion diagnostics. A further new chapter addresses CRISPR, outlining and discussing the complex pattern of oppositions and appeals in the EPO concerning this revolutionary, Nobel prize winning technology. Thus, the current jurisprudence of the Boards of Appeal of the EPO is systematically organized according to the following topics:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eProducts of Nature: What is Patentable in the EPO (compounds, stem cells, plants, etc.)\u003c\/li\u003e\n\u003cli\u003eThe Person Skilled in the Art\u003c\/li\u003e\n\u003cli\u003eThe Principles Applied by the Technical Boards in Assessing the Disclosure of a Document and their Implications\u003c\/li\u003e\n\u003cli\u003eThe Principles Applied by the Technical Boards in Claim Construction\u003c\/li\u003e\n\u003cli\u003ePlausibility as a Means to Assess Quid Pro Quo\u003c\/li\u003e\n\u003cli\u003eThe Principles of Patenting Medical and Diagnostic Uses\u003c\/li\u003e\n\u003cli\u003ePatenting Nucleic Acid Inventions\u003c\/li\u003e\n\u003cli\u003ePatenting Protein Inventions\u003c\/li\u003e\n\u003cli\u003ePatenting Antibody Inventions\u003c\/li\u003e\n\u003cli\u003ePatenting Microorganisms and Fermentation Technologies\u003c\/li\u003e\n\u003cli\u003ePatenting Viruses\u003c\/li\u003e\n\u003cli\u003ePatenting Stem Cells and Cell-based Therapeutics\u003c\/li\u003e\n\u003cli\u003ePatenting Nucleic Acid Amplification Technologies\u003c\/li\u003e\n\u003cli\u003ePatenting Nucleic Acid Modification Technologies: CRISPR et al.\u003c\/li\u003e\n\u003cli\u003ePatenting Next Generation Sequencing Technologies\u003c\/li\u003e\n\u003cli\u003ePatenting Personalized Medicines and Companion Diagnostics\u003c\/li\u003e\n\u003cli\u003ePatenting Plants and Animals\u003c\/li\u003e\n\u003cli\u003ePriority   Hurdles of Same Subject Matter and Legal Entitlement\u003c\/li\u003e\n\u003cli\u003eDeposit\u003c\/li\u003e\n\u003cli\u003eHow to draft a European Patent Application and Claims\u003c\/li\u003e\n\u003cli\u003eA Brief Introduction to the Extension of Patent Terms\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eAs is evident, this expanded version of »From Clones to Claims« solely focuses on EPO Appeal Board jurisprudence and SPCs. It no longer addresses jurisprudence from the US or Japan as a consequence of the technically limited space in such a product. Thus, the new version is a detailed guide on how to prepare European patent applications in any particular field of biopharmaceuticals and how to best defend the European patents once granted. Given this, the book is not only useful for advanced practitioners, but also for beginners as an introduction into and an orientation to the field of biotechnology patents.\u003c\/p\u003e\u003cp\u003eGiven the book's clear language and systematic structure, the EPO's jurisprudence is\u003c\/p\u003e","brand":"Buchserien.de","offers":[{"title":"Neuware","offer_id":53985879327058,"sku":"9783452298232","price":269.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0615\/7002\/3593\/files\/unnamed_b189e24c-6897-417a-9b3c-57e974c0b531.jpg?v=1783891724","url":"https:\/\/www.buchserien.de\/products\/from-clones-to-claims","provider":"Buchserien.de","version":"1.0","type":"link"}